The proposed acquisition consideration represents an equity value of $2.4 billion and an enterprise value of $2.5 billion, Sumitovant Biopharma said in a statement.
(Reporting by Anirudh Saligrama in Bengaluru)
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
390 JPY | -3.70% |
|
+10.17% | -16.31% |
05-14 | Transcript : Sumitomo Pharma Co., Ltd., 2024 Earnings Call, May 14, 2024 | |
05-14 | Sumitomo Pharma Co., Ltd. Provides Consolidated Earnings Guidance for the Year Ending March 31, 2024 | CI |
(Reuters) - Sumitovant Biopharma said on Sunday the company and its parent Sumitomo Pharma Co Ltd had submitted a non-binding offer to acquire Myovant Sciences Ltd.
The proposed acquisition consideration represents an equity value of $2.4 billion and an enterprise value of $2.5 billion, Sumitovant Biopharma said in a statement.
(Reporting by Anirudh Saligrama in Bengaluru)
1st Jan change | Capi. | |
---|---|---|
-16.31% | 1B | |
+56.08% | 815B | |
+43.42% | 641B | |
-5.50% | 352B | |
+17.89% | 314B | |
+11.24% | 303B | |
+16.75% | 242B | |
+2.49% | 224B | |
+14.19% | 218B | |
+9.69% | 168B |